

# **Navana Pharmaceuticals PLC.**

**Financial Statements (Un-audited) for  
Third Quarter (Q3), FY 2024-25**

***Period: 1<sup>st</sup> July 2024 - 31<sup>th</sup> March 2025***



**Navana Pharmaceuticals PLC.**  
**Statement of Financial Position (Un-audited)**  
**As at 31 March 2025**

(Amount in BDT)

Particulars	Notes	As at	
		31-Mar-2025	30-Jun-2024
<b>Assets</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	3.00	5,053,681,137	4,650,941,337
Intangible Asset	3.01	165,000	330,000
Capital Work in Progress	4.00	740,375,561	931,717,844
Right-of-Use Asset	5.00	100,413,822	163,404,672
Investment in Marketable Securities (Fair Value)	6.00	38,723,870	76,920,238
<b>Total Non-Current Assets</b>		<b>5,933,359,390</b>	<b>5,823,314,091</b>
<b>Current Assets:</b>			
Inventories	7.00	1,807,822,786	1,283,188,710
Trade and Other Receivables	8.00	832,694,779	1,020,129,897
Advances, Deposits and Prepayments	9.00	1,779,766,586	2,151,093,999
Goods In Transit	10.00	847,159,625	758,207,036
Cash and Cash Equivalents	11.00	200,072,248	267,770,086
<b>Total Current Assets</b>		<b>5,467,516,024</b>	<b>5,480,389,728</b>
<b>Total Assets</b>		<b>11,400,875,414</b>	<b>11,303,703,819</b>
<b>Equity And Liabilities</b>			
<b>Equity:</b>			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium	13.00	448,170,069	448,170,069
Revaluation Reserve	14.00	1,848,295,335	1,848,295,335
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(144,011,059)	(123,143,306)
Retained Earnings		1,035,514,504	708,021,144
<b>Total Equity</b>		<b>4,867,721,167</b>	<b>4,561,095,560</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities:</b>			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	51,872,167	64,500,095
Long Term Loan	17.02	61,909,753	115,319,266
Bond		80,000,000	80,000,000
Deferred Tax Liability	18.00	173,972,956	158,005,471
<b>Total Non-Current Liabilities</b>		<b>397,754,876</b>	<b>447,824,832</b>
<b>Current Liabilities:</b>			
Short Term Loan	19.00	4,603,139,067	5,008,191,502
Lease Liabilities (Current Maturity)	16.01	33,253,637	43,553,958
Long Term Loan (Current Maturity)	17.00	111,547,220	35,366,036
Trade and Other Payables	20.00	1,374,488,214	1,199,906,960
Unclaim Dividend Payable	39.00	12,971,233	7,764,971
<b>Total Current Liabilities</b>		<b>6,135,399,371</b>	<b>6,294,783,427</b>
<b>Total Liabilities</b>		<b>6,533,154,247</b>	<b>6,742,608,259</b>
<b>Total Equity and Liabilities</b>		<b>11,400,875,414</b>	<b>11,303,703,819</b>
<b>Net Asset Value (NAV) Per Share</b>	<b>30.00</b>	<b>45.32</b>	<b>42.46</b>

Annexed notes are integral part of these financial statements.

Finance Director & CFO

Company Secretary

Acting Managing Director

Director

Director


**Navana Pharmaceuticals PLC.**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the period from 01 July 2024 to 31 March 2025**


Particulars	Notes	Interim Period		(Amount in BDT)	
		Third Quarter			
		July 2024- March'2025	July 2023- March'2024	Jan-March'2025	Jan-March'2024
<b>Net Sales</b>	21.00	<b>6,604,436,742</b>	<b>5,032,377,101</b>	<b>2,240,718,731</b>	<b>1,748,739,278</b>
Less: Cost of Good Sold	22.00	3,565,890,580	2,738,507,958	1,228,942,581	984,524,181
<b>Gross Profit</b>		<b>3,038,546,162</b>	<b>2,293,869,143</b>	<b>1,011,776,150</b>	<b>764,215,097</b>
<b>Less: Operating Expenses</b>					
Administrative Expenses	23.00	157,651,134	143,334,588	53,579,737	63,621,604
Selling & Marketing Expenses	24.00	1,369,257,119	1,063,286,050	509,002,531	341,856,605
Distribution Expenses	25.00	414,519,918	349,819,128	125,441,333	111,979,148
<b>Total Operating Expenses</b>		<b>1,941,428,171</b>	<b>1,556,439,766</b>	<b>688,023,601</b>	<b>517,457,357</b>
<b>Operating Profit</b>		<b>1,097,117,991</b>	<b>737,429,377</b>	<b>323,752,549</b>	<b>246,757,740</b>
Less: Finance Expenses	26.00	565,981,270	297,668,525	172,737,198	97,654,000
Add: Other Income/(loss)	27.00	(25,119,893)	1,504,079	(26,574,469)	(11,688,685)
<b>Profit before WPPF &amp; Tax</b>		<b>506,016,828</b>	<b>441,264,931</b>	<b>124,440,882</b>	<b>137,415,055</b>
Contribution to WPPF		24,096,039	21,012,616	5,925,756	6,543,574
<b>Profit before tax</b>		<b>481,920,788</b>	<b>420,252,315</b>	<b>118,515,126</b>	<b>130,871,481</b>
<b>Less: Income Tax</b>		<b>106,976,415</b>	<b>88,646,106</b>	<b>10,448,591</b>	<b>23,583,480</b>
Current Tax	28.00	112,884,898	88,717,806	28,507,507	31,177,263
Deferred Tax Expense/(Income)		(5,908,483)	(71,700)	(18,058,916)	(7,593,784)
<b>Profit after Tax</b>		<b>374,944,373</b>	<b>331,606,209</b>	<b>108,066,535</b>	<b>107,288,001</b>
<b>Other Comprehensive Income</b>					
Unrealized Gain/(loss) on Marketable Security		(20,867,753)	(40,940,887)	(2,334,886)	(23,800,487)
<b>Total Comprehensive Income</b>		<b>354,076,620</b>	<b>290,665,322</b>	<b>105,731,649</b>	<b>83,487,514</b>
<b>Earnings Per Share (EPS)</b>	<b>29.00</b>	<b>3.49</b>	<b>3.09</b>	<b>1.01</b>	<b>1.00</b>

Annexed notes are integral part of these financial statements.

  
Finance Director & CFO

  
Company Secretary

  
Acting Managing Director

  
Director

  
Director



**Navana Pharmaceuticals PLC.**  
**Statement of Changes in Equity (Un-audited)**  
**For the period from 01 July 2024 to 31 March 2025**

**As at 31 March 2025**

**(Amount in BDT)**

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2024	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(123,143,306)	708,021,144	4,561,095,560
Profit after Tax	-	-	-	-	-	-	374,944,373	374,944,373
14% Cash Dividend for YE 30 June 2024	-	-	-	-	-	-	(47,451,013)	(47,451,013)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	(20,867,753)	-	(20,867,753)
	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(144,011,059)	1,035,514,504	4,867,721,167

**Navana Pharmaceuticals PLC.**  
**Statement of Changes in Equity (Un-audited)**  
**For the period from 01 July 2023 to 31 March 2024**


**As at 31 March 2024**

Particulars	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(46,800,998)	443,028,348	4,372,445,072
Profit after Tax during the period	-	-	-	-	-	-	331,606,209	331,606,209
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	-	-	(750,000,018)	-	-	-	-	(750,000,018)
13% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(139,641,082)	(139,641,082)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	-	(40,940,887)	-	(40,940,887)
	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(87,741,885)	634,993,475	4,523,469,312

  
Finance Director & CFO

  
Company Secretary

  
Acting Managing Director

  
Director

  
Director



**Navana Pharmaceuticals PLC.**  
**Statement of Cash Flows (Un-audited)**  
**For the period from 01 July 2024 to 31 March 2025**

(Amount in BDT)

Particulars	Notes	Interim Period	
		July2024- March'2025	July2023- March'2024
<b>Cash Flows from Operating Activities:</b>			
Cash Received from Customers		6,794,629,272	4,943,185,102
Cash Received from Other Income		19,325,559	6,288,326
Cash Paid to Operational & Others		(5,715,804,773)	(4,778,473,343)
<b>Net cash flows from operating Activities:</b>		<b>1,098,150,059</b>	<b>171,000,086</b>
<b>Cash Flows from Investing Activities:</b>			
Cash Paid for Purchase of Property, Plant & Equipment		(214,285,154)	(440,545,130)
Realized Gain/(loss) from Sale of Marketable Securities		(10,457,145)	971,866
Cash received from Dividend Income		901,146	930,336
Cash Received/(Paid) from Investment in Marketable Securities		38,196,368	14,357,289
<b>Net cash from/(used in) investing activities:</b>		<b>(185,644,785)</b>	<b>(424,285,639)</b>
<b>Cash Flows from Financing Activities:</b>			
Dividend Paid		(42,244,751)	(131,496,940)
Bank & Lease Interest Paid		(534,259,615)	(307,205,954)
Payment against Short Term Borrowings		(405,052,435)	540,831,494
Receipts against Long Term Borrowings		22,771,671	43,442,216
Payment against Lease Liability		(22,928,249)	(4,354,112)
<b>Net cash from/(used in) financing activities</b>		<b>(981,713,379)</b>	<b>141,216,705</b>
<b>Change in Cash and Cash Equivalent</b>		<b>(69,208,105)</b>	<b>(112,068,849)</b>
Cash and Cash Equivalent at the beginning of the period		267,770,086	440,930,216
Effect of Exchange Rate Changes on Cash and Cash Equivalents		1,510,267	60,204
<b>Cash and Cash Equivalent at the end of the period</b>		<b>200,072,248</b>	<b>328,921,571</b>
<b>Net Operating Cash Flow per Share (NOCFPS)</b>	31.00	<b>10.22</b>	<b>1.59</b>

Finance Director & CFO

Company Secretary

Acting Managing Director

Director

Director

**Navana Pharmaceuticals PLC.**  
**Notes to the Interim Financial Statements (Un-Audited)**  
**For the period 01 July 2024 to 31 March 2025**

**1.0 About the Company**

**1.01 Legal Form of the Company**

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

**1.02 Address of the Registered Office and Factory**

The address of the Company's registered office and factory 1071,1073, North Rupshi, Tarabo, Municipality, Rupganj, Narayanganj. Corporate office address is House 99, Road 4, Block # B, Banani Dhaka-1213, Bangladesh. The Company has its factory in Rupshi, Narayanganj and several depots around the country.

**1.03 Nature of Business Activities**

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

**2.00 Basis of Preparation and Presentation of Financial Statements**

**2.01 Preparation and Presentation of Financial Statements of the Company**

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals PLC.

These interim financial statements should be read in conjunction with the Financial Statements for the year ended June 30, 2024 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting.

**Interim Financial Reporting:**

Interim period is a financial reporting period shorter than a full financial period. Interim financial report means a financial report containing either a complete set of financial statements (as described in IAS 1 Presentation of Financial Statements) or a set of condensed financial statements for an interim period.

IAS 34 requires that condensed Interim Financial Statements contain at a minimum:

- a condensed statement of financial position;
- a condensed statement or condensed statements of profit or loss and other comprehensive income;
- a condensed statement of changes in equity;
- a condensed statement of cash flows; and
- selected explanatory notes.

These Interim Financial Statements present selected explanatory notes that are intended to assist users in understanding the results of the operations of the company for the current interim period.

The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.



## **2.02 Statement of Compliance**

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

## **2.03 Regulatory Compliances**

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax Ordinance 1984 and The Income Tax Act 2023;
- b) The Income Tax Rules 1984 and The Income Tax Act 2023;;
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969;
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

## **2.04 Basis of Measurement**

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.

## **2.05 Reporting Period and Comparative Information**

The Financial Statements cover 09 months period starting from July 01, 2024 to March 31, 2025

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IAS & IFRS whenever it is relevant for the understanding of the current period financial statements.

## **2.06 Rearrangement of Financial Statement:**

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

## **2.07 Functional and Presentation Currency**

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

## **2.08 Property, Plant and Equipment (PPE)**

### **Recognition and Measurement:**

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.



### Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

### Subsequent Costs

The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenance costs are charged to the Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they incurred.

### Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

### Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Depreciation on Property, Plant and Equipment has been computed during the periods using reducing balance method except Land & Land Development. Depreciation has been charged on addition when the related PPE are available.

After considering the useful life of assets as per IAS 16, the annual depreciation rates have been applied as under which is considered reasonable by the management.

#### Rate of Depreciation:

Particulars	Rate	Particulars	Rate
<b>Land and Land Development</b>		<b>Vehicles</b>	
Land and Land Development	Nil	Transport & Vehicles	20%
<b>Building &amp; Other Construction</b>		Motor Cycle	20%
Factory Building	10%	<b>Furniture &amp; Fixture</b>	
Office Decoration	10%	Furniture & Fixtures	10%
Pump House Construction	20%	Rack & Pallets	15%
<b>Particulars</b>	<b>Rate</b>	<b>Particulars</b>	<b>Rate</b>
Store Room	15%	<b>Office Equipment's</b>	
Office Room Extension	10%	Fire Extinguishers	15%
Factory Decoration	10%	Office Equipment's	15%
Factory Wall	10%	Air Cooler	20%
Pre Fabrication Building	10%	Cookeries & Cutlery	10%
Solvent Store	15%	Telephone Line Installation	15%
<b>Plant &amp; Machinery</b>		Photocopier & Fax Machine	20%
Plant & Machinery	10%	Projector	15%
Electrical Installation	20%	Refrigerator	20%
Generator	20%	Mobile	20%
Gas Line Installation	20%	<b>Computer &amp; IT Accessories</b>	
Spare Parts	20%	Computer	25%
ETP	20%	IT Accessories	30%
Electric Sub Station	20%	<b>Other Assets</b>	
<b>Lab Equipment</b>		Sundry Assets	15%
Quality Control Equipment	15%	Books	10%
Tools & Equipment's	15%	Software	20%

### 2.09 Intangible Assets

Software are amortized over 5 periods based on straight line method from the date when assets are available for use. The amount of amortization has been presented under the statement of rate of amortization on software is as under.

### 2.10 Events after the Reporting Period

Events after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
<b>3.00 Property, Plant and Equipment: Tk. 5,053,681,137</b>			
This is made up as follows: (details shown in Annex A)			
<b>Cost</b>			
Opening Balance		3,647,483,437	2,650,971,843
Addition during the period		595,659,619	1,012,118,013
Adjustment/disposal during the period		(312,784)	(15,606,419)
<b>Closing Balance</b>		<b>4,242,830,272</b>	<b>3,647,483,437</b>
<b>Revaluation</b>			
Opening Balance		1,966,271,632	1,966,271,632
Adjustment due to revaluation during the period		-	-
<b>Closing Balance</b>		<b>1,966,271,632</b>	<b>1,966,271,632</b>
<b>Total Cost &amp; Revaluation</b>		<b>6,209,101,903</b>	<b>5,613,755,069</b>
<b>Depreciation</b>			
Opening Balance		962,813,731	806,861,796
Charged during the period		192,802,790	171,251,750
Adjustment during the period		(195,761)	(15,299,814)
<b>Closing Balance</b>		<b>1,155,420,760</b>	<b>962,813,731</b>
<b>Written Down Value</b>		<b>5,053,681,137</b>	<b>4,650,941,337</b>
<b>3.01 Intangible Assets: Tk. 165,000</b>			
This is made up as follows:			
<b>Cost</b>			
Opening Balance		1,100,000	1,100,000
Addition during the period		-	-
<b>Total Cost</b>		<b>1,100,000</b>	<b>1,100,000</b>
<b>Depreciation</b>			
Opening Balance		770,000	550,000
Charged during the period		165,000	220,000
<b>Closing Balance</b>		<b>935,000</b>	<b>770,000</b>
<b>Written Down Value</b>		<b>165,000</b>	<b>330,000</b>
<b>4.00 Capital Work In Progress: Tk. 740,375,561</b>			
This is made up as follows:			
Opening Balance		931,717,844	614,665,799
<b>Addition during the period:</b>			
Construction of New Utility and Engineering Building	90,745		31,773,650
Refurbishment of Cephalosporin Unit	-		73,159,298
BMRE and Machinery	302,354,621		939,095,421
CWIP-New Generic Building 1	35,317,331		-
Modernization and expansion of General liquid facility with dispensing area	-		37,977,309
Modernization and expansion of Animal health facility	15,020,000		10,448,737
	<b>1,284,500,541</b>		<b>1,707,120,214</b>
<b>Less: Capitalized during the period</b>			
Capitalized in Factory Building	(544,124,980)		(775,402,370)
<b>Closing Balance</b>	<b>740,375,561</b>		<b>931,717,844</b>
<b>5.00 Right-of-Use Asset: Tk. 100,413,822</b>			
This is made up as follows: (Details shown in Annex B)			
<b>Written Down Value</b>		<b>100,413,822</b>	<b>163,404,672</b>
<b>6.00 Investment in Marketable Securities (Fair Value): Tk. 38,723,870</b>			
This is made-up as follows:			
Opening total cost of marketable securities	200,063,544		214,420,832
Cost value of sales of share	(17,328,616)		(14,357,288)
<b>Closing balance cost Value</b>	<b>182,734,928</b>		<b>200,063,544</b>
Unrealized gain/(loss)	(144,011,059)		(123,143,306)
<b>Closing market value securities</b>	<b>38,723,870</b>		<b>76,920,238</b>

During the period total Realized Gain/(loss) from sale of marketable securities is (Tk.) (10,457,154)



Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
<b>7.00 Inventories: Tk. 1,807,822,786</b>			
This is made-up as follows:			
	Raw Material	527,921,001	473,451,176
	Packing Material	140,769,532	141,963,452
	Finished Goods	926,518,111	565,590,306
	Work-in-Process	115,469,217	77,078,776
	Printed & Gifted Promotional Stock	97,144,926	25,105,000
	<b>Total</b>	<b>1,807,822,786</b>	<b>1,283,188,710</b>
<b>8.00 Trade and Other Receivables: Tk. 832,694,779</b>			
This is made-up as follows:			
	Receivables-Local	699,304,875	915,824,397
	Receivables-Export	106,753,339	80,738,506
	Export Cash Incentive Receivable	26,345,189	23,106,132
	Interest Receivable on FDR	250,361	460,862
	Dividend Receivable	41,014	-
	<b>Total</b>	<b>832,694,779</b>	<b>1,020,129,897</b>
Export Receivable as at 31 March 2025 total \$882,259 has been translated @ Tk. 121 average spot rate and resulting unrealized gain of Tk. 1,510,267 has been reported under 'FOREX Gain/Loss Account'.			
<b>9.00 Advances, Deposits and Prepayments: Tk. 1,779,766,586</b>			
This is made-up as follows:			
	Advance for Suppliers (others)	34,697,188	86,570,654
	Advance for Raw/Packing Purchase	196,335,340	261,120,477
	LC Margin for Raw Material	61,435,871	117,828,568
	VAT Paid on Finished Goods	132,629,055	131,166,700
	Security Money	500,582	6,344,210
	Advance to Depot	54,486,886	44,189,884
	Advance Against Salary & Allowanc	9,610,529	11,977,354
	Advance Against Lease for Vehicles	847,524	847,524
	Advance Against Rent Sales Center	12,839,480	-
	Advance Against Customs Duty	19,939,823	23,662,933
	Advance Income Tax	635,773,672	520,416,189
	Advance for Capital Expense	604,701,636	920,949,505
	LC Margin for Capital Goods	15,969,000	26,020,000
	<b>Total</b>	<b>1,779,766,586</b>	<b>2,151,093,999</b>
<b>10.00 Goods In Transit: Tk. 847,159,625</b>		<b>847,159,625</b>	<b>758,207,036</b>
<b>11.00 Cash and Cash Equivalents: Tk. 200,072,248</b>			
This is made-up as follows:			
<b>Cash at Bank</b>			
	Jamuna Bank Ltd., Rupshi Br. A/c. 1661	3,345	211,619
	Pubali Bank Ltd., Dhaka Stadium Br. A/c 473	6,490,918	12,933,628
	Southeast Bank Ltd., Corporate Br. CD A/C No.648	916,439	1,106,015
	Southeast Bank Ltd., Corporate Br. CD A/C No 7614	290,954	328,852
	Dutch Bangla Bank Ltd., Local Office, CD A/C No.957	8,589,975	4,375,173
	Sonali Bank Ltd., Customs House Br. A/c 379	6,559,942	5,061,575
	Al Arafah Islami Bank Ltd., VIP Road Br. A/c-7189	236,056	6,466,843
	Al Arafah Islami Bank Ltd., VIP Road Br. ERQ A./c-46	222,045	1,580,147
	Al Arafah Islami Bank Ltd., VIP Road Br.DAD A./c-44	2,441,222	2,543,943
	United Commercial Bank Ltd., Gulshan Br., A./c-0011	13,123,235	21,411,461
	United Commercial Bank Ltd., Gulshan Br. A/c-0055	3,657	4,207
	United Commercial Bank Ltd., SND A.C-162	2,730	3,075
	Dhaka Bank Ltd.. Banani Br. A/c-28321	-	(237)
	NRBC Bank Ltd., Gulshan Br. -SND 033	99,200	99,200
	Shimanto Bank Ltd.Corp. Br., CD-012	944,009	2,895,595
	Community Bank BD Ltd.-9101	-	307,829
	Bengal Commercial Bank, Corp Br.-1467	1,001,783	292,139
	One Bank, Principal Br. A/c 9942	1,665	1,665
	Pubali Bank Ltd. Faridpur Br. A./c-160	23,801	1,115,563
	Pubali Bank Ltd., Mymensingh Br.- A/c 294	196,915	500,790
	Pubali Bank Ltd., Dargagate Br. A./c-125	1,156	285,130
	Pubali Bank Ltd., Kamalpur Br., A/c-25303	1,979	623
	Pubali Bank Ltd., Maizdee Court Br. A./c-840	230,180	823,985
	Pubali Bank Ltd., Momin Road Br. A./c-8940	8,520	2,624
	Southeast Bank Ltd., Barisal Br. A./c-051	2,630	3,915



Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
	Southeast Bank Ltd., Bogra Br. A./c-246	353	923
	Southeast Bank Ltd., Comilla Br. A./c-044	357	928
	Southeast Bank Ltd., Corporate Br.A./c-8200	2,811	3,270
	Southeast Bank Ltd., Cox's Bazar Br. A./c-091	435	54,900
	Southeast Bank Ltd., Dinajpur Br.-A/c 0144	724	2,020
	Southeast Bank Ltd., Jessore(SME) Br. A./c-347	476	936
	Southeast Bank Ltd., Joydevpur Br., A./c-027	7,259	10,891
	Southeast Bank Ltd., Khulna Br. A./c-925	385	845
	Southeast Bank Ltd., Rajshahi Br. A./c-014	1,159	1,954
	Southeast Bank Ltd., Rangpur Br. A./c-284	3,266	4,547
	United Commercial Bank, Br Ac-304	309,757	4,368
	United Commercial Bank, Br Ac-462	1,447	4,368
	United Commercial Bank, Br Ac-362	275,907	709,368
	United Commercial Bank, Br Ac-328	401,333	479,368
	United Commercial Bank, Br Ac-168	305,333	149,368
	United Commercial Bank, Br Ac-268	7,448	571,368
	United Commercial Bank, Br Ac-164	101,447	1,368
	United Commercial Bank, Br Ac-183	4,873	34,368
	United Commercial Bank, Br Ac-334	448	184,368
	United Commercial Bank, Br Ac-188	333	4,368
	United Commercial Bank, Br Ac-358	10,448	814,368
	United Commercial Bank, Br Ac-034	6,723	519,643
	United Commercial Bank, Br Ac-247	6,908	1,150,368
	United Commercial Bank, Feni-0138	871,528	604,988
	Standard Chartered Bank Ltd.Gulshan Br. Ac CD-28001	314,806	306,071
	United Commercial Bank, Tangail A/c-4138	6,674	299,938
	United Commercial Bank, Pabna A/c-8094	993	1,028
	United Commercial Bank, Feni A/c-138	871,527	-
	Prime Bank Banani Branch A/C 26074	5,685,234	-
	Dhaka Bank PLC.. Rupshi Br. A/c-000174	753,908	-
	City Bank Plc A/C # 6001	2,878	-
	Meghna Bank Plc # 110113500000181	841,098	4,195
	United Commercial Bank, Bond A/c-2258	3,620	4,166
	Commercial Bank of Ceylon PLC 7841	9,655	9,655
	AIBL SND , Ac # 0141220032027	138,042	10,381
	United Commercial Bank, N'Ganj Ac-10079	2,878	899,913
	FDR at IPDC AC-25213	3,000,000	3,000,000
	FDR at SCB AC-8001	30,000,000	30,000,000
	United Commercial Bank Ltd., IPO A/c-3209	67,831,632	120,119,623
	AIBL-141220031994 (13% Cash Dividend)	8,482,568	5,448,991
	United Commercial Bank Ltd. Ac-1971 (11% Cash Dividend)	4,669,949	2,338,190
	Meghna Bank Plc # 110113500000190 (14% Dividend)	5712801.83	-
	<b>Cash in Hand</b>	<b>28,030,479</b>	<b>37,659,326</b>
	<b>Total</b>	<b>200,072,248</b>	<b>267,770,086</b>

a. The reconciliation of bank balance has been performed and found in order.

b. Cash in hand has been counted by the management at the period end.

#### 12.00 Paid-up Share Capital: Tk. 1,074,162,170

This is made-up as follows:

##### A. Authorised Capital:

200,000,000 Ordinary Shares of Tk. 10 each

2,000,000,000 2,000,000,000

##### B. Issued Subscribed & Paid up Capital:

107,416,217 Ordinary Shares of Tk. 10 each

1,074,162,170 1,074,162,170

##### Closing Balance

1,074,162,170 1,074,162,170

#### 13.00 Share Premium: Tk. 44,170,069

Opening Balance

448,170,069 448,170,069

Addition during the period

- -

Less: Adjustment for IPO Expenses

- -

##### Closing Balance

448,170,069 448,170,069

The Company has issued 27,186,067 nos. of ordinary shares through IPO for aggregating Tk.750,000,000 , out of which 9,753,441 nos. of ordinary shares issued for Eligible Investors (EIs) and Employee & Others at the cut-off price Tk. 34 and remaining 17,432,626 nos. of ordinary shares at discounted price Tk.24 from the cut-off price i.e. Tk 34 per share for General Public (GP)including NRBs.

Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
<b>14.00 Revaluation Reserve: Tk. 1,848,295,335</b>			
	This is made-up as follows:		
	Opening Balance	1,848,295,335	1,848,295,335
	Less: Adjusted during the period	-	-
	<b>Revaluation Reserve:</b>	<b>1,848,295,335</b>	<b>1,848,295,335</b>
<b>15.00 Loan from Directors: Tk. 30,000,000</b>			
	This is made-up as follows:		
	Opening Balance	30,000,000	30,000,000
	<b>Closing Balance</b>	<b>30,000,000</b>	<b>30,000,000</b>
<b>16.00 Lease Liabilities: Tk. 85,125,804</b>			
	This is made-up as follows:		
	<b>Opening balance</b>	108,054,053	124,315,723
	Add: Addition during the year for ROUA for Vehicle & HO	16,360,533	-
	Less: Payment during the year	(39,288,783)	(16,261,670)
	<b>Closing balance</b>	<b>85,125,804</b>	<b>108,054,053</b>
<b>16.01 Principal Payment due within one period</b>		33,253,637	43,553,958
<b>16.02 Principal Payment due within two to five period</b>		51,872,167	64,500,095
<b>Total</b>		<b>85,125,804</b>	<b>108,054,053</b>
<b>17.00 Long Term Loan: Tk. 173,456,973</b>			
	This is made-up as follows:		
<b>17.01 Payment due within one period</b>		111,547,220	35,366,036
<b>17.02 Principal Payment due more than one year</b>		61,909,753	115,319,266
<b>Total</b>		<b>173,456,973</b>	<b>150,685,302</b>
<b>18.00 Deferred Tax Liability: Tk. 173,972,956</b>			
	This is made-up as follows:		
	Opening Balance	146,501,877	169,640,474
	Addition during the year:	5,908,483	-
	<b>Total</b>	<b>152,410,360</b>	<b>146,501,877</b>
	<b>Less: Deferred Tax Asset</b>	<b>(21,562,596)</b>	<b>(11,503,594)</b>
	<b>Net Deferred Tax Liability Balance</b>	<b>173,972,956</b>	<b>158,005,471</b>
<b>19.00 Short Term Loan: Tk. 4,603,139,066</b>			
	This is made-up as follows:		
	Bank Overdraft	1,862,241,624	1,886,549,502
	LTR, UPAS Loan	1,635,850,573	1,673,542,529
	Time Loan	987,274,420	1,334,659,639
	Margin Loan for Investment in Securities	117,772,449	113,439,831
		<b>4,603,139,066</b>	<b>5,008,191,502</b>
<b>20.00 Trade and Other Payables: Tk. 1,374,488,214</b>			
	This is made-up as follows:		
	Trade & other Payables	47,869,806	23,791,543
	Salary Payables	105,885,811	110,666,864
	VAT Payable	56,124,094	53,676,568
	Payable Audit Fee	236,250	402,500
	Payable for Other Supplies	1,285,990	824,352
	Payable Director Remuneration	594,080	584,290
	Payable-Sales Center Rent	1,823,258	1,421,075
	Payable for Utility	3,596,212	701,891
	Provision for Gratuity	54,100,383	70,184,257
	Provision for Bad Debt	16,553,209	13,064,358
	Provision for Broken, Damage & Expiry	24,958,012	312,486
	Provision for Income Tax	564,085,462	451,200,564
	Provision for W.P.F	17,200,189	25,139,919
	Interest Payable on Short Term Loan	198,054,106	167,225,310
	Interest Payable on Term Loan	1,094,908	949,389
	Interest Payable on Lease Liability	747,340	-
	Withholding Tax Payable	5,267,357	4,049,848
	Payable for Earned Leave Encashment	13,367,853	13,367,853
	Payable for TDS and VDS for Capex	258,843,894	262,343,894
	Payable for interest on Bond	2,800,000	-
	<b>Total</b>	<b>1,374,488,214</b>	<b>1,199,906,960</b>



Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24
<b>21.00</b>	<b>Sales: Tk. 6,604,436,742</b>		
	This is made-up as follows:		
	Local Sales Human Health	6,226,252,999	4,697,934,229
	Export Sales	302,722,998	168,832,129
	Local Sales Animal Health	1,171,958,936	1,011,867,568
	<b>Gross sales</b>	<b>7,700,934,933</b>	<b>5,878,633,926</b>
	Less: Value Added Tax (VAT)	1,096,498,191	846,256,825
	<b>Net sales</b>	<b>6,604,436,742</b>	<b>5,032,377,101</b>
	<b>Breakup of Net Turnover</b>		
	Local Sales Human Health Division	5,303,452,299	4,001,647,555
	Export Sales	302,722,998	168,832,129
	Local Sales Animal Health Division	998,261,445	861,897,417
	<b>Total</b>	<b>6,604,436,742</b>	<b>5,032,377,101</b>
	a. Sales figure is presented on net of VAT in the statement of profit or loss and other comprehensive income.		
	b. Sales has increased due to strong branding, marketing and improved economic condition.		
<b>22.00</b>	<b>Cost of Sales: Tk. 3,565,890,580</b>		
	This is made-up as follows:		
	Raw Material Consumption (Note No: 21.01)	2,387,947,364	1,849,430,700
	Packing Material Consumption (Note No: 21.02)	1,187,456,416	764,909,571
	Factory Expenses (Note No: 21.03)	461,499,366	376,722,004
	<b>Total Manufacturing Cost</b>	<b>4,036,903,145</b>	<b>2,991,062,275</b>
	Opening Stock Work-In-Process	77,078,776	96,348,470
	Closing Stock Work-In-Process	(115,469,217)	(104,947,905)
	<b>Cost of Production</b>	<b>3,998,512,704</b>	<b>2,982,462,841</b>
	Opening Stock Finished Goods	565,590,306	508,936,313
	<b>Finished goods available for sale</b>	<b>4,564,103,011</b>	<b>3,491,399,154</b>
	Cost of Physician Sample transferred to Marketing Exp.	(33,361,740)	(26,658,648)
	Cost of Bonus Product transferred to Marketing Exp.	(38,332,580)	(24,255,215)
	Closing Stock Finished Goods	(926,518,111)	(701,977,332)
	<b>Cost of Goods Sold</b>	<b>3,565,890,580</b>	<b>2,738,507,959</b>
<b>22.01</b>	<b>Raw Material Consumption: Tk. 2,387,947,364</b>		
	This is made-up as follows:		
	Opening Stock of Raw Materials	473,451,176	378,760,941
	Add: Purchase during the period	2,442,417,188	1,769,867,528
	Less: Closing Stock of Raw Materials	(527,921,001)	(299,197,769)
	<b>Total</b>	<b>2,387,947,364</b>	<b>1,849,430,700</b>
<b>22.02</b>	<b>Packing Material Consumption: Tk. 1,187,456,416</b>		
	This is made-up as follows:		
	Opening Stock of Packing Materials	141,963,452	113,570,761
	Add: Purchase during the period	1,186,262,496	790,841,664
	Less: Closing Stock of Packing Materials	(140,769,532)	(139,502,854)
	<b>Total</b>	<b>1,187,456,416</b>	<b>764,909,571</b>
<b>22.03</b>	<b>Factory Expenses: Tk. 461,499,366</b>		
	This is made-up as follows:		
	Salary & Allowance	129,640,930	134,001,682
	Festival Bonus	14,442,941	14,336,291
	Contribution to Provident Fund	7,254,619	4,995,077
	Holiday Allowance & Overtime	15,769,112	12,826,326
	Cylinder Expenses	-	522,000
	Diesel for generator	8,129,430	4,782,553
	Electricity Bill	25,958,705	28,342,970
	Entertainment	644,784	3,210,422
	Renewal Fees	260,498	413,235
	Fees & Forms	15,733	465,056
	Insurance Premium-Fire & Burglary	3,240,379	1,178,511
	Gas Bill	1,652,243	1,546,424
	Earned leave encashment	4,361,395	-
	Group Insurance Premium	-	59,510
	Laboratory Chemicals	22,385,044	12,255,541
	Medical Expenses	33,850	32,958



Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24
	Newspaper & Periodicals	12,438	2,469
	Repair & Maintenance	18,431,588	5,309,084
	Medical Waste Management Expense	2,258,481	1,408,959
	Sanitation Expense	5,493,000	2,435,268
	Spare Parts for machinery	10,690,785	12,168,318
	Depreciation on PPE & ROUA	141,072,416	104,362,549
	Other Business Expenses	49,750,996	32,066,800
	<b>Total</b>	<b>461,499,366</b>	<b>376,722,004</b>

**23.00 Administrative Expenses: Tk. 157,651,134**

This is made-up as follows:

Salary and Allowances	59,377,125	54,653,381
Festival Bonus	8,559,959	5,969,279
Contribution to Provident Fund	3,454,795	3,943,473
Gratuity	4,648,302	3,750,000
Earned leave encashment	3,878,146	-
Audit Fees	316,875	262,500
Board Meeting Fee	517,000	555,500
Audit Committee & NRC Meeting Fee	467,500	236,500
Professional Fees	2,900,663	973,998
Advertising Expenses	1,460,502	1,257,352
Director's Remuneration	5,970,000	7,542,000
Electricity Bill	2,118,153	2,396,593
Registration Fees and Renewal Fees	497,015	742,348
Foreign Tour Expenses	3,180,808	7,330,176
Depreciation on Rental Asset (Annex-ROUA)	7,824,607	5,628,055
Depreciation Other than Rental Asset (Annex-PPE)	18,539,816	14,107,083
Amortization on Software	165,000	165,000
Other Business Expenses	33,774,868	33,821,349
<b>Total</b>	<b>157,651,134</b>	<b>143,334,588</b>

As per IFRS 16-Leases Office Rent for current period has been presented under Depreciation.

**24.00 Selling & Marketing Expenses: Tk. 1,369,257,119**

This is made-up as follows:

Salary and Allowances	685,772,871	482,628,265
Festival Bonus	71,348,875	67,102,973
Contribution to Provident Fund	34,528,802	27,487,980
Incentives	45,692,827	18,095,784
Gratuity	5,174,266	2,250,000
Stationery	1,318,340	2,463,213
Daily Expenses for Field workers	269,422,997	264,801,180
Earned leave encashment	8,206,528	-
Travelling and Conveyance	8,196,919	5,811,414
Bonus On Sales	38,332,580	24,255,215
Printed & Gifted Promotional Expenses	52,959,072	28,068,144
Sample Expenses	33,361,740	26,658,648
Depreciation on PPE & ROUA	15,058,269	9,384,810
Product Expiry Replacement	31,280,081	23,074,997
Brand Development & New Product	10,404	4,515,763
Other Business Expenses	68,592,548	76,687,663
<b>Total</b>	<b>1,369,257,119</b>	<b>1,063,286,050</b>

**25.00 Distribution Expenses: Tk. 414,519,918**

This is made-up as follows:

Salary and Allowances	123,524,109	115,037,500
Festival Bonus	17,001,359	13,850,835
Contribution to Provident Fund	7,125,995	4,177,151
Repair & Maintenance	4,532,819	2,139,607
Stationery	5,594,068	4,696,003
Earned Leave Encashment	3,931,486	-
Daily Expenses for Field workers	56,128,715	50,512,016
Holiday Allowance & Overtime	6,983,639	3,723,291
Insurance Premium Fire & Burglary	498,000	254,179
Group Insurance Premium	-	99,510
Depreciation on PPE & ROUA	89,772,275	56,764,583
Other Business Expenses	99,427,454	98,564,452
<b>Total</b>	<b>414,519,918</b>	<b>349,819,128</b>



Notes	Particulars	Amount in BDT	
		01 Jul'24-31 Mar'25	01 Jul'23-31 Mar'24

**26.00 Finance Expenses: Tk. 565,981,270**

This is made-up as follows:

Interest Charged on Short term loan	522,101,106	253,464,057
Interest on Term Loan	8,428,010	10,177,592
Bank Charges	5,548,144	5,412,416
Interest on Other Loan/(Bond)	8,490,795	-
Bank Charges-Export	992,945	3,454,032
BO Charges, Interest on Margin Loan	10,016,975	12,522,546
Interest on Lease Finance	10,403,296	12,637,883
<b>Total</b>	<b>565,981,270</b>	<b>297,668,525</b>

**27.00 Other Income/ (Loss): Tk. -25,119,893**

This is made-up as follows:

Cash Incentive	16,376,577	10,260,111
Bank Interest	305,240	119,280
Interest on FDR	436,391	189,645
Dividend Income	901,146	930,336
Sale of Wastage	4,068,337	4,153,176
FOREX Gain/(Loss)	(38,466,927)	(24,200,924)
Gain on disposal of FA	(74,523)	1,460,000
Realized Gain/(loss) from Sale of Marketable Securities	(10,457,145)	971,866
Income from PF Contribution Forfeiture	1,791,012	7,620,588
<b>Total</b>	<b>(25,119,893)</b>	<b>1,504,079</b>

**28.00 Income Tax: Tk. 106,976,415**

This is made-up as follows:

Current Period Tax	112,884,898	88,717,806
Deferred Tax Expense/ (Income)	(5,908,483)	(71,700)
<b>Total</b>	<b>106,976,415</b>	<b>88,646,106</b>

**29.00 Earnings Per Share (EPS)**

Earnings Attributable to the Ordinary Shareholders	374,944,373	331,606,209
Weighted Avg. Number of Ordinary Shares	107,416,217	107,416,217
<b>Earnings Per Share (EPS)</b>	<b>3.49</b>	<b>3.09</b>

**Reasons for Deviation:** Increment of Earnings per Share in the reporting period by 12.94% because of growth of Sales Revenue as well as optimum cost management policy.

**Weighted Average Number of Ordinary Shares Outstanding:** The weighted average number of ordinary shares outstanding during the year is the number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares issued during the year multiplied by a time-weighted factor. The time-weighted factor is the number of days that the shares are outstanding as a proportion of the total number of days in the year (considering 365 days in a period).

Weighted Average Number of Ordinary Shares Outstanding during the year:

Date of Allotment	Ordinary Shares Nos	Weighted no. days	Calculation	Weighted no. Shares
OS Shares as on 1st July ,2022	80,230,150	100%		80,230,150
16/10/2022	23,201,750	365	(23,201,750*365/365)	23,201,750
19/10/2022	3,984,317	365	(3,984,317*365/365)	3,984,317
Closing Balance as on 31-03-2025	<b>107,416,217</b>			<b>107,416,217</b>

- 29.01 Dilution of Earnings Per Share:** No diluted earnings per share is required to be calculated for the period presented as there was no item issued by the company, as such no scope for dilution of shares during the period.



Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024
<b>30.00 Net Asset Value (NAV) Per Share</b>		<b>31-Mar-2025</b>	<b>30-June-2024</b>
Total Assets		11,400,875,414	11,303,703,819
Less Total Liabilities		6,533,154,247	6,742,608,259
<b>Net Assets</b>		<b>4,867,721,167</b>	<b>4,561,095,560</b>
Number of Ordinary Shares		107,416,217	107,416,217
<b>Net Asset Value (NAV) Per Share</b>		<b>45.32</b>	<b>42.46</b>
<b>31.00 Net Operating Cash Flow Per Share (NOCFPS)</b>			
Net Cash Generated from Operating Activities		1,098,150,059	171,000,086
Number of Ordinary Shares		107,416,217	107,416,217
<b>Net Operating Cash Flow Per Share (NOCFPS)</b>		<b>10.22</b>	<b>1.59</b>

**Reasons for Deviation:** Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 10.22 from Tk. 1.59 due to cash received from the customers was higher than the cash payment for operation in the reporting period.

### 32.00 Reconciliation of Cash Flows from Operating Activities

A reconciliation of net income or net profit with cash flow from operating activities:

	July 2024-March'2025	July 2023-March'2024
<b>Net Profit before tax</b>	<b>481,920,788</b>	<b>420,252,315</b>
<b>Adjustment to reconcile net income to net cash provided by operating activities:</b>		
Depreciation and Amortization	272,319,175	190,247,081
Realized Gain/(loss) on Marketable Securities	(10,457,145)	(971,866)
Dividend Income	(901,146)	(930,336)
Unrealized Foreign Exchange Gain/(Loss)	(38,466,927)	26,182
Bank & Lease Interest	534,259,615	297,668,525
WPPF Provision	17,200,189	21,012,616
Income Tax Paid	115,357,483	(52,173,590)
<b>Increase/Decrease in Current Assets:</b>		
Inventory and Goods in transit (Increase)	(613,586,665)	(128,554,587)
Accounts Receivable (Increase)	187,435,119	(82,160,674)
Advance Deposit & Prepayment (Increase)	319,453,947	114,439,847
<b>Increase/Decrease in current Liabilities:</b>		
Trade and Other Payables (Decrease)	(166,384,375)	(163,162,925)
<b>Net Cash Generated by Operating Activities</b>	<b>1,098,150,058</b>	<b>615,692,588</b>

### 33.00 Events After the Reporting Period

There are no significant events after the reporting period to present.

### 34.00 Related Party Disclosure

The name of the related parties nature of transaction and their respective period end balance have been set out in accordance with the provisions of Para 18 Disclosure of Transaction between Related Parties of IAS 24 'Related Party Disclosure's. The company in normal course of business carried out transactions at fair value with following related parties:

Name of the Related Party	Relationship	Nature of Transaction	Balance as at 1 July 2024	Transaction July'24-Mar'25	Balance as at 31 Mar 2024
Professor Dr. Jonaid Shafiq	Managing Director	Remuneration	308,320	2,671,782	303,863
Dr. Sayeed Ahmed	Deputy Managing Director	Remuneration	275,970	2,340,540	282,467

As per Para-17, IAS 24: An entity shall disclose key management personnel compensation in total and for each of the following

(a) Short-term Employee Benefits	Designation	Particulars	Transaction during the period	Outstanding as on 31-03-2024
<b>Name</b>				
Professor Dr. Jonaid Shafiq	Managing Director	Director Remuneration	2,671,782	303,863
Dr. Sayeed Ahmed	Deputy Managing Director	Director Remuneration	2,340,540	282,467



Notes	Particulars	Amount in BDT	
		31-Mar-2025	30-Jun-2024

**35.00 Contingent Assets**

There was no contingent assets as at 31 March 2025.

**36.00 Contingent Liability**

**110,976,846**

**110,976,846**

**37.00 Litigation Pending**

1. For Non-payment of VAT which the legal experts estimated cost is Tk. 40,000,000/-. It has been stayed by High Court till 04-11-2024
2. VAT demand of Tk. 31,982,604.12/- for Animal Health Product- "Pusti Premix". It was stayed by High Court on 14-01-2016 until final verdict of court.
3. Demand for Non-payment of VAT & interest to the extent to Tk. 8,666,739.22 by Customs Excise & VAT Commissionerate Dhaka (East) against Navana Health Care past audit reports. It has been stayed by High Court till 28-08-2024.
4. A petition is filed with High Court against unreasonable demand of Tk. 30,327,503 by Income Tax Tribunal u/s 83(2)/156/159 for AY 2015-16 (11 month).
5. A petition has been filed with Jugma Zilla Judge Court of Narayanganj for reclaiming 30 decimal land opposite of Factory at Rupshi Rupgonj. It is expected to be favorable.

**37.01 Bank Guarantee on behalf of the company provided by following Banks:**

1. Al-Arafah Islami Bank PLC. VIP Road Branch-Tk. 8,245,391.52/-.
2. Bengal Commercial Bank PLC, Head Office-Tk. 6,56,500/-.
3. Community Bank Bangladesh PLC, Corporate Branch-Tk. 81,53,881.49/-.

**38.00 Events after the Reporting Period**

Navana Pharmaceuticals PLC. allotted total 23,201,750 no's shares to General & EI Shareholders and 3,984,317 nos shares to Employees & Other Shareholders on 16-10-2022 and 19-10-2022 respectively to raise the IPO Proceed of Tk.75.00 crore

**39.00 Unclaim Dividend Payable: Tk. 12,971,233**

**Year wise Break-up**

2021-2022

2022-2023

2023-2024

**Total**

**31-Mar-2025**

**30-June-2024**

**12,971,233**

**7,764,971**

2,024,967

2,336,928

5,235,359

5,428,043

5,710,907

-


**12,971,233**

**7,764,971**

  
Finance Director & CFO

  
Company Secretary

  
Acting Managing Director

  
Director

  
Director



**Navana Pharmaceuticals PLC.**  
Schedule of Property, Plant and Equipment  
As at 31 March 2025

SL No.	Particulars	COST										Dep. Rate	DEPRECIATION				Written Down Value 31 Mar 2025	Written Down Value 30 June 2024
		Balance as on 01 July 2024			Addition			Adjustment	Balance as on 31 Mar 2025				Balance as on 01 July 2024	Charged during the year	Adjustment	Balance as on 31 Mar 2025		
		Cost	Revaluation Reserve	Total	Cost	Revaluation Reserve	Total		Cost	Revaluation Reserve	Total							
1	Land and Land Development	516,631,355	1,966,271,633	2,482,902,988	-	-	-	-	516,631,355	1,966,271,633	2,482,902,988	-	-	-	-	-	2,482,902,988	2,482,902,988
	Land and Land Development	516,631,355	1,966,271,633	-	-	-	-	-	516,631,355	1,966,271,633	2,482,902,988	0%	-	-	-	-	2,482,902,988	2,482,902,988
2	Building & Other Construction	1,414,819,374	-	1,414,819,374	284,718,200	-	284,718,200	-	1,699,537,574	-	1,699,537,574	-	345,532,818	86,033,122	-	431,565,942	1,267,971,632	1,069,286,556
	Factory Building	1,332,778,148	-	1,332,778,148	284,718,200	-	284,718,200	-	1,617,496,348	-	1,617,496,348	10%	307,805,087	82,709,249	-	390,514,336	1,226,982,012	1,024,973,062
	Office Decoration	17,328,480	-	17,328,480	-	-	-	-	17,328,480	-	17,328,480	10%	10,060,567	545,093	-	10,605,660	6,722,820	7,267,913
	Pump House Construction	3,970	-	3,970	-	-	-	-	3,970	-	3,970	20%	-	-	-	3,970	-	-
	Store Room	27,480	-	27,480	-	-	-	-	27,480	15%	27,244	-	27,480	15%	27,244	27	209	236
	Office Room Extension	829,201	-	829,201	-	-	-	-	829,201	10%	727,953	-	829,201	10%	727,953	7,594	93,654	101,248
	Factory Decoration (BMRE)	48,150,595	-	48,150,595	-	-	-	-	48,150,595	10%	14,432,189	-	48,150,595	10%	14,432,189	2,528,880	16,961,069	31,189,526
	Factory Wall	3,177,143	-	3,177,143	-	-	-	-	3,177,143	10%	3,177,143	-	3,177,143	10%	2,440,192	55,271	2,495,463	681,680
	Pre Fabrication Building	12,445,429	-	12,445,429	-	-	-	-	12,445,429	10%	9,966,067	-	12,445,429	10%	9,966,067	185,952	10,152,019	2,293,410
	Solvent Store	78,928	-	78,928	-	-	-	-	78,928	15%	78,928	-	78,928	15%	69,551	1,055	70,606	8,322
3	Plant & Machinery	1,322,674,143	-	1,322,674,143	285,153,296	-	285,153,296	-	1,607,827,439	-	1,607,827,439	-	432,588,991	84,938,193	-	517,527,185	1,090,300,255	890,085,153
	Plant & Machinery	1,275,934,972	-	1,275,934,972	285,153,296	-	285,153,296	-	1,561,088,268	-	1,561,088,268	10%	393,360,731	83,750,923	-	477,111,654	1,083,976,614	882,574,242
	Electrical Installation	23,147,818	-	23,147,818	-	-	-	-	23,147,818	20%	18,958,472	-	23,147,818	20%	18,958,472	628,871	3,560,475	4,189,346
	Generator	14,447,896	-	14,447,896	-	-	-	-	14,447,896	20%	12,324,351	-	14,447,896	20%	12,324,351	378,696	12,703,047	1,744,849
	Gas Line Installation	3,101,333	-	3,101,333	-	-	-	-	3,101,333	20%	2,206,929	-	3,101,333	20%	2,206,929	134,161	2,341,090	760,243
	Spare Parts	1,501,405	-	1,501,405	-	-	-	-	1,501,405	20%	1,380,170	-	1,501,405	20%	1,380,170	18,185	1,398,355	103,050
	ETP	660,080	-	660,080	-	-	-	-	660,080	20%	530,822	-	660,080	20%	530,822	19,389	550,211	109,869
	Electric Sub Station	3,880,639	-	3,880,639	-	-	-	-	3,880,639	20%	3,827,517	-	3,880,639	20%	3,827,517	7,968	3,835,485	45,154
4	Lab Equipment	118,336,060	-	118,336,060	2,247,474	-	2,247,474	-	120,583,534	-	120,583,534	-	72,559,806	5,218,270	-	77,778,076	42,805,458	45,776,254
	Quality Control Equipment	114,974,900	-	114,974,900	2,247,474	-	2,247,474	-	117,222,374	-	117,222,374	15%	69,529,833	5,170,969	-	74,700,802	42,521,572	45,445,067
	Tools & Equipment's	3,361,160	-	3,361,160	-	-	-	-	3,361,160	15%	3,361,160	-	3,361,160	15%	3,029,973	47,301	3,077,274	283,886
5	Furniture & Fixture	62,126,502	-	62,126,502	9,427,937	-	9,427,937	-	71,554,439	-	71,554,439	-	26,669,226	3,748,227	-	30,417,453	41,136,986	35,457,276
	Furniture & Fixtures	33,456,435	-	33,456,435	2,238,837	-	2,238,837	-	35,695,272	-	35,695,272	10%	18,405,408	1,225,218	-	19,630,626	16,064,647	15,051,027
	Rack & Pallets	28,670,067	-	28,670,067	7,189,100	-	7,189,100	-	35,859,167	-	35,859,167	15%	8,263,818	2,523,009	-	10,786,827	25,072,340	20,406,249
6	Office Equipment's	47,908,014	-	47,908,015	7,566,095	-	7,566,095	312,784	55,161,325	-	55,161,325	-	33,133,088	2,408,719	195,761	35,346,046	19,815,279	14,774,927
	Fire Extinguishers	1,074,615	-	1,074,615	-	-	-	-	1,074,615	15%	1,074,615	-	1,074,615	15%	945,520	14,523	960,043	114,572
	Office Equipment's	19,319,609	-	19,319,609	368,750	-	368,750	-	19,688,359	15%	19,688,359	-	13,847,426	635,414	-	14,482,840	5,205,519	5,472,183
	Air Cooler	21,052,934	-	21,052,934	7,194,345	-	7,194,345	312,784	27,934,495	20%	27,934,495	-	12,596,637	1,670,835	195,761	14,071,711	13,862,784	8,456,297
	Cookeries & Cutleries	416,096	-	416,096	-	-	-	-	416,096	10%	416,096	-	416,096	10%	338,275	5,837	344,112	71,984
	T-telephone Line Installation	1,192,479	-	1,192,479	3,000	-	3,000	-	1,195,479	15%	1,195,479	-	1,003,020	21,314	-	1,024,334	171,145	189,459
	Photocopier & Fax Machine	441,300	-	441,300	-	-	-	-	441,300	20%	441,300	-	405,399	5,385	-	410,784	30,516	35,901
	Projector	770,500	-	770,500	-	-	-	-	770,500	15%	770,500	-	591,459	20,142	-	611,601	158,899	179,041
	Refreratorator A/H	1,703,275	-	1,703,275	-	-	-	-	1,703,275	20%	1,703,275	-	1,500,296	30,447	-	1,530,743	172,532	202,979
	Mobile	1,937,206	-	1,937,206	-	-	-	-	1,937,206	20%	1,937,206	-	1,905,056	4,823	-	1,909,879	27,328	32,150
7	Transport	106,726,523	-	106,726,523	-	-	-	-	106,726,523	-	106,726,523	-	8,001,495	7,404,627	-	15,406,122	91,320,401	98,725,028
	Vehicle	106,726,523	-	106,726,523	-	-	-	-	106,726,523	10%	106,726,523	-	8,001,495	7,404,627	-	15,406,122	91,320,401	98,725,028
8	Computer & IT Accessories	50,322,470	-	50,322,470	5,923,870	-	5,923,870	-	56,246,340	-	56,246,340	-	38,153,888	2,819,134	-	40,973,022	15,273,318	12,168,582
	Computer	40,568,759	-	40,568,759	5,923,870	-	5,923,870	-	46,492,629	25%	46,492,629	-	28,879,389	2,729,115	-	31,608,504	14,884,125	11,689,370
	Hardware & Networking Installation	9,753,711	-	9,753,711	-	-	-	-	9,753,711	25%	9,753,711	-	9,274,499	90,019	-	9,364,518	389,193	479,212
9	Other Assets	7,938,991	-	7,938,991	622,745	-	622,745	-	8,561,736	-	8,561,736	-	6,174,419	232,498	-	6,406,917	2,154,819	1,764,572
	Sundry Assets	7,012,304	-	7,012,304	485,745	-	485,745	-	7,498,049	15%	7,498,049	-	5,309,568	227,860	-	5,537,428	1,960,621	1,702,736
	Books	926,687	-	926,687	137,000	-	137,000	-	1,063,687	10%	1,063,687	-	864,851	4,638	-	869,489	194,198	61,836
	TOTAL 31 March 2025:	3,647,483,433	1,966,271,634	5,613,755,067	595,659,618	-	595,659,618	312,784	4,242,830,267	1,966,271,634	6,209,101,900	-	962,813,730	192,802,790	195,761	1,155,420,763	5,053,681,137	4,650,941,337
10	Intangible Assets	-	-	-	-	-	-	-	-	-	-	20%	770,000	165,000	-	935,000	165,000	550,000
	Software	1,100,000	-	1,100,000	-	-	-	-	1,100,000	-	1,100,000	20%	770,000	165,000	-	935,000	165,000	550,000

Allocation of depreciation:				
Particulars	Total	Admin	Factory	Sales & Mkt
PPE excl Vehicle	185,398,163	18,539,816	129,778,714	7,415,927
Vehicle	7,404,627	-	-	7,404,627



## Navana Pharmaceuticals PLC.

## Schedule of Right-of-Use Asset

As at 31 March 2025

SL No.	Particulars	Cost				Dep. Rate	Depreciation				Written Down Value as on 31 Mar 2025	Written Down Value as on 30 June 2024
		Balance as on 1 July 2024	Addition	Adjustment	Balance as on 31 Mar 2024		Balance as on 1 July 2024	Charged during the year	Adjustment	Balance as on 31 Mar 2025		
		Cost	Cost		Total							
1	Rental Asset	16,952,283	16,360,533	-	33,312,816		7,064,023	4,060,040	-	11,124,063	22,188,754	9,888,260
	Rental Asset	16,952,283	16,360,533	-	33,312,816		7,064,023	4,060,040	-	11,124,063	22,188,754	9,888,260
2	Vehicles	501,942,299	-	-	501,942,299		348,425,886	75,291,345	-	423,717,231	78,225,068	153,516,413
	Transport & Vehicles	321,673,275		-	321,673,275	20%	222,456,345	48,250,991	-	270,707,336	50,965,939	99,216,930
	Motor Cycle	180,269,024	-	-	180,269,024	20%	125,969,541	27,040,354	-	153,009,895	27,259,129	54,299,483
	<b>Total</b>	<b>518,894,582</b>	<b>16,360,533</b>	<b>-</b>	<b>535,255,115</b>		<b>355,489,909</b>	<b>79,351,385</b>	<b>-</b>	<b>434,841,294</b>	<b>100,413,822</b>	<b>163,404,673</b>

## Allocation of depreciation:

	Total	Admin	Factory	Sales & Mkt	Dist.
On Vehicles	75,291,345	3,764,567	11,293,702	7,529,134	52,703,941
On Rent HO	4,060,040	4,060,040	-	-	-

**Navana Pharmaceuticals PLC.**  
House 99, Road 04, Block B, Banani, Dhaka 1213  
TIN: 187576149869/Taxes Circle 156 (Companies)

**COMPUTATION OF TOTAL INCOME AND TAX LIABILITY**  
Assessment Year 2025-26  
Income Year ended 31 March 2025

		<b>Amounts in Taka</b>
<b>NET PROFIT, BEFORE TAXATION</b>		
- As per Profit and Loss Statement		48,19,20,788
<b>Less: Other income -</b>		
Cash incentive	1,63,76,577	
Bank interest	3,05,240	
Interest on FDR	4,36,391	
Dividend income	901,146	
Sale of wastage	40,68,337	
Gain on disposal of FA	-74,523	
Realized Gain/(loss) on Share Sell	-10,457,145	
PF Forfeiture	17,91,012	1,33,47,034
		46,85,73,755
<b>ADDITIONS FOR SUBSEQUENT/ SEPERATE CONSIDERATIONS</b>		
<b>Add: Accounting depreciation</b>	26,82,59,135	
- Depreciation on ROUA	4,060,040	
- Entertainment	73,95,945	
- Incentive	4,56,92,827	
- Sample expenses	3,33,61,740	
- Gratuity provision	1,50,00,000	
- WPPF provision	4,30,12,722	
- Broken/ damaged provision	2,27,06,897	
- Promotional Expense	5,29,59,072	
- Bad debt provision	63,01,714	
- Interest On Loan	56,59,81,270	
- Foreign tour	1,01,72,547	107,49,03,910
		154,34,77,664
<b>ADJUSTMENTS FOR STATUTORY DISALLOWANCES</b>		
<b>Less : Depreciation as per Income Tax Act 2023</b>		348,072,064
<b>Less : Rent of ROUA</b>		4,060,040
<b>Less: Interest Paid On Loan</b>		53,42,59,615
		65,70,85,945
<b>Less: Sample expenses</b>		
Total turnover	6,604,436,742	
On first 5 crore @ 2%	1,000,000	
On Next 5 crore @ 1%	500,000	
Balance @ 0.5%	32,522,184	
<b>Allowable</b>	<b>34,022,184</b>	3,40,22,184
		62,30,63,761
<b>Add: Profit on disposal of vehicle</b>		62,30,63,761
<b>Less: Gratuity paid</b>	1,04,50,000	
WPPF Paid	2,58,12,533	
Bad debt written off	3,12,159	
Incentive @10% of Profit	4,81,92,079	
Foreign tour @ 0.5% of disclosed turnover or the actual expenditure, whichever is less.	1,01,72,547	12,79,61,502
		49,51,02,259
<b>Less: Entertainment allowance permissible as per rule , on profit before tax claim of entertainment allowance @4% on the first Taka 10,00,000 of income at @ 2% on the balance income.The lower amount is allowed, as permissible.</b>		73,95,945
		48,77,06,314
<b>Less:</b>		
Export sale @ 7%		2,23,54,657
<b>INCOME FROM LOCAL BUSINESS</b>		46,53,51,657
<b>INCOME FROM EXPORT BUSINESS</b>		2,23,54,657
<b>Total</b>		<b>48,77,06,314</b>



**COMPUTATION OF TOTAL INCOME AND TAX LIABILITY**  
Assessment Year 2025-26  
Income Year ended 31 March 2025

<u>Add: Other income -</u>			
Cash incentive	1,63,76,577		
Bank interest	3,05,240		
Interest on FDR	4,36,391		
Sale of wastage	40,68,337		
Gain on disposal of FA	-74,523		
Dividend Income	9,01,146		
Realized Gain from Share Sale	(10,457,145)		
INCOME FROM OTHER INCOME			1,33,47,034
TOTAL INCOME			50,10,53,348
<u>Calculation of minimum tax</u>			
(i) (a) On business income @ 22.5%	10,47,04,123		
(b) On other income excluding Capital Gain @ 20%	12,44,243	10,59,48,366	
(ii) On turnover @ 0.60%		3,96,26,620	
Minimum tax -- higher of (i) and (ii)			10,59,48,366
<u>Calculation of tax on export income</u>			
(i) Tax at regular rate @20%	26,82,559		
Less: Rebate @ 50% (under paragraph 28 of Part A of the Sixth Schedule)	13,41,279		
	13,41,279		
(ii) Tax deducted at source	30,02,894		
Minimum tax -- higher of (i) and (ii)			30,02,894
<u>Calculation tax on Cash Incentive:</u>			
Cash Incentive tax thereon 22.5%	3,684,730		36,84,730
<u>Calculation tax on Bank Interest:</u>			
Bank Interest tax thereon 22.5%	68,679		68,679
<u>Calculation tax on Dividend:</u>			
Dividend tax thereon 20%	180,229		1,80,229
<b>Total Tax Liability</b>			<b>11,28,84,898</b>

Navana Pharmaceuticals PLC

TIN: 187576149869/Taxes Circle 156 (Companies)

Calculation of deferred tax

Assessment Year 2025-26

Income for the year ended 31 March 2025

Deferred tax liability/(asset)

Particulars	Carrying amount of assets and liabilities as at 31-03-25	Tax base value of assets and liabilities as a 31-03-2025	Taxable/(Deducti ble) temporary difference	DTL	DTA	Opening Balance	Current Yr Charge
	Taka	Taka	Taka	Taka	Taka	Taka	Taka
PPE	2,570,778,149	2,185,483,922	385,294,226	86,691,201	-	28,525,579	58,165,622
Revaluation Reserve	-	-	-	-	-	117,976,298	-
ROUA	100,413,822	204,048,547	(103,634,725)	(23,317,813)	-	-	(23,317,813)
Intangible	165,000	633,600	(468,600)	(105,435)	-	-	(105,435)
Lease liability Vehicle	(82,412,184)	-	(82,412,184)	-	(18,542,741)	-	(18,542,741)
Lease liability ROUA	(2,713,619)	-	(2,713,619)	-	(610,564)	-	(610,564)
Marketable Securities	38,723,870	182,734,928	(144,011,058)	-	(14,401,106)	-	(14,401,106)
Prov. For Gratuity	(15,000,000)	10,450,000	(4,550,000)	-	(1,023,750)	-	(1,023,750)
Interest Paid On Loan	565,981,270	534,259,615	31,721,655	-	7,137,372	-	7,137,372
Prov. For WPPF	(17,200,189)	-	(17,200,189)	-	(3,870,043)	-	(3,870,043)
Prov. For Broken, Damage, Expiry	(24,958,012)	-	(24,958,012)	-	(5,615,553)	-	(5,615,553)
Prov. For Bad debt	(16,553,209)	-	(16,553,209)	-	(3,724,472)	-	(3,724,472)
Net temporary difference	3,117,224,897	3,117,610,613	20,514,284	63,267,953	(40,650,857)	146,501,877	(5,908,483)